Literature DB >> 31160868

Intranasal Esketamine (SpravatoTM) for Use in Treatment-Resistant Depression In Conjunction With an Oral Antidepressant.

Rebecca Bahr, Alicia Lopez, Jose A Rey.   

Abstract

Intranasal esketamine for treatment-resistant depression.

Entities:  

Keywords:  esketamine; ketamine; suicidal ideation; suicide; treatment-resistant depression

Year:  2019        PMID： 31160868      PMCID： PMC6534172     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  13 in total

1.  Ropanicant (SUVN-911), an α4β2 nicotinic acetylcholine receptor antagonist intended for the treatment of depressive disorders: pharmacological, behavioral, and neurochemical characterization.

Authors:  Ramakrishna Nirogi; Renny Abraham; Pradeep Jayarajan; Venkatesh Goura; Rajesh Kallepalli; Rajesh Babu Medapati; Jayaprakash Tadiparthi; Vinod Kumar Goyal; Santosh Kumar Pandey; Ramkumar Subramanian; Surendra Petlu; Jagadeesh Babu Thentu; Veera Raghava Chowdary Palacharla; Shankar Reddy Gagginapally; Abdul Rasheed Mohammed; Venkat Jasti
Journal:  Psychopharmacology (Berl)       Date:  2022-03-17       Impact factor: 4.530

2.  Investigational Drugs for the Treatment of Depression (Part 2): Glutamatergic, Cholinergic, Sestrin Modulators, and Other Agents.

Authors:  Octavian Vasiliu
Journal:  Front Pharmacol       Date:  2022-06-17       Impact factor: 5.988

Review 3.  Psychedelic Medicines in Major Depression: Progress and Future Challenges.

Authors:  Jose Carlos Bouso; Genís Ona; Rafael G Dos Santos; Jaime E C Hallak
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Prophylactic (R,S)-Ketamine Is Effective Against Stress-Induced Behaviors in Adolescent but Not Aged Mice.

Authors:  Alessia Mastrodonato; Ina Pavlova; Noelle C Kee; Van Anh Pham; Josephine C McGowan; J John Mann; Christine A Denny
Journal:  Int J Neuropsychopharmacol       Date:  2022-06-21       Impact factor: 5.678

5.  Envisioning Post-pandemic Digital Neurological, Psychiatric and Mental Health Care.

Authors:  Amit Khanna; Graham B Jones
Journal:  Front Digit Health       Date:  2021-12-21

6.  Tyrosine 121 moves revealing a ligandable pocket that couples catalysis to ATP-binding in serine racemase.

Authors:  Chloe R Koulouris; Sian E Gardiner; Tessa K Harris; Karen T Elvers; S Mark Roe; Jason A Gillespie; Simon E Ward; Olivera Grubisha; Robert A Nicholls; John R Atack; Benjamin D Bax
Journal:  Commun Biol       Date:  2022-04-11

Review 7.  The Therapeutic Potential of Psilocybin.

Authors:  Henry Lowe; Ngeh Toyang; Blair Steele; Henkel Valentine; Justin Grant; Amza Ali; Wilfred Ngwa; Lorenzo Gordon
Journal:  Molecules       Date:  2021-05-15       Impact factor: 4.411

8.  Disrupting the α7nAChR-NR2A protein complex exerts antidepressant-like effects.

Authors:  Anlong Jiang; Ping Su; Shupeng Li; Albert H C Wong; Fang Liu
Journal:  Mol Brain       Date:  2021-07-05       Impact factor: 4.041

9.  Ketamine in Major Depressive Disorder: Mechanisms and Future Perspectives.

Authors:  Cheolmin Shin; Yong-Ku Kim
Journal:  Psychiatry Investig       Date:  2020-03-23       Impact factor: 2.505

Review 10.  Glutamate and depression: Reflecting a deepening knowledge of the gut and brain effects of a ubiquitous molecule.

Authors:  Adejoke Yetunde Onaolapo; Olakunle James Onaolapo
Journal:  World J Psychiatry       Date:  2021-07-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.